Diagnosis and Treatment of Basal Cell Carcinoma in Specialized Dermatology Units: A Clinical Practice Guideline

被引:8
作者
Vilchez-Marquez, F. [1 ]
Borregon-Nofuentes, P. [2 ]
Barchino-Ortiz, L. [3 ]
Ruiz-de-Casas, A. [4 ]
Palacios-Alvarez, I. [5 ]
Soria-Rivas, A. [6 ]
Descalzo-Gallego, M. A. [7 ]
Garcia-Doval, I. [7 ,8 ]
Rios-Buceta, L. [9 ]
Redondo-Bellon, P. [5 ]
机构
[1] Hosp Guadix, Serv Dermatol, Granada, Spain
[2] Clin Betere Marcos, Serv Dermatol, Madrid, Spain
[3] Hosp Gen Univ Gregorio Maranon, Serv Dermatol, Madrid, Spain
[4] Hosp Univ Virgen Macarena, Serv Dermatol, Seville, Spain
[5] Clin Univ Navarra, Serv Dermatol, Pamplona, Spain
[6] Hosp Univ Ramon y Cajal, Serv Oncol, Madrid, Spain
[7] Acad Espanola Dermatol & Venereol, Fdn Piel Sana, Unidad Invest, Madrid, Spain
[8] Complexo Hosp Univ Vigo, Serv Dermatol, Vigo, Pontevedra, Spain
[9] Hosp Univ Ramon y Cajal, Serv Dermatol, Madrid, Spain
来源
ACTAS DERMO-SIFILIOGRAFICAS | 2020年 / 111卷 / 04期
关键词
Basal cell carcinoma; Clinical practiceguidelines; Neoplasms of skin; Therapy; Evidence-based medicine; MOHS MICROGRAPHIC SURGERY; AMINOLEVULINATE PHOTODYNAMIC THERAPY; TOPICAL METHYL AMINOLEVULINATE; ORGAN TRANSPLANT RECIPIENTS; SURGICAL EXCISION; SKIN-CANCER; RECURRENT BASAL; EUROPEAN GUIDELINES; RISK; CRYOSURGERY;
D O I
10.1016/j.ad.2019.07.006
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background and objective: Basal cell carcinoma (BCC) is the most common skin cancer in the general population. BCC is managed in a variety of ways, and available international guidelines are difficult to put into practice in Spain. This guideline aims to improve the management of BCC based on current evidence and provide a point of reference for Spanish dermatologists. Material and methods: Members of the Spanish Oncologic Dermatology and Surgery Group (GEDOC) with experience treating BCC were invited to participate in drafting this guideline. The drafters used the ADAPTE collaboration process to develop the new guideline based on existing ones, first summarizing the care pathway and posing relevant clinical questions. They then searched for guidelines, assessed them with the AGREE II (Appraisal of Guidelines for Research and Evaluation) tool, and searched the selected guidelines for answers to the clinical questions. Finally, the recommendations were drafted and submitted for external review. Results: The highest-scoring guidelines were from the Association of Dermatologists, the National Comprehensive Cancer Network, the European Dermatology Forum, and the European Academy of Dermatology and Venereology. A total of 11 clinical questions were answered. Conclusions: This new guideline answers the working group's clinical questions about the routine management of BCC in Spain. It provides dermatologists with a tool they can use for decision making while taking into consideration the resources available and patient preferences. (c) 2020 AEDV. Published by Elsevier Espana, S.L.U. This is an open access article under the CC-BYNC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:291 / 299
页数:9
相关论文
共 79 条
[1]   An investigator-initiated open-label clinical trial of vismodegib as a neoadjuvant to surgery for high-risk basal cell carcinoma [J].
Ally, Mina Sarah ;
Aasi, Sumaira ;
Wysong, Ashley ;
Teng, Claudia ;
Anderson, Eric ;
Bailey-Healy, Irene ;
Oro, Anthony ;
Kim, Jinah ;
Chang, Anne Lynn ;
Tang, Jean Yuh .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2014, 71 (05) :904-U304
[2]  
[Anonymous], ACT GUIAS PRACT CLIN
[3]  
[Anonymous], NCCN GUID LIN TREATM
[4]  
[Anonymous], 2009, Oxford Centre for Evidence-Based Medicine Levels of Evidence
[5]   Treatment of basal cell carcinoma with curettage alone [J].
Barlow, James O. ;
Zalla, Mark J. ;
Kyle, Amber ;
DiCaudo, David J. ;
Lim, Katherine K. ;
Yiannias, James A. .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2006, 54 (06) :1039-1045
[6]   Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial [J].
Basset-Seguin, Nicole ;
Hauschild, Axel ;
Grob, Jean-Jacques ;
Kunstfeld, Rainer ;
Dreno, Brigitte ;
Mortier, Laurent ;
Ascierto, Paolo A. ;
Licitra, Lisa ;
Dutriaux, Caroline ;
Thomas, Luc ;
Jouary, Thomas ;
Meyer, Nicolas ;
Guillot, Bernard ;
Dummer, Reinhard ;
Fife, Kate ;
Ernst, D. Scott ;
Williams, Sarah ;
Fittipaldo, Alberto ;
Xynos, Ioannis ;
Hansson, Johan .
LANCET ONCOLOGY, 2015, 16 (06) :729-736
[7]  
Bernardeau K, 2000, ANN DERMATOL VENER, V127, P175
[8]   A randomized study of minimal curettage followed by topical photodynamic therapy compared with surgical excision for low-risk nodular basal cell carcinoma [J].
Berroeta, L. ;
Clark, C. ;
Dawe, R. S. ;
Ibbotson, S. H. ;
Fleming, C. J. .
BRITISH JOURNAL OF DERMATOLOGY, 2007, 157 (02) :401-403
[9]   THE USE OF MOHS MICROGRAPHIC SURGERY FOR DETERMINATION OF RESIDUAL TUMOR IN INCOMPLETELY EXCISED BASAL-CELL CARCINOMA [J].
BIELEY, HC ;
KIRSNER, RS ;
REYES, BA ;
GARLAND, LD .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1992, 26 (05) :754-756
[10]   Histological evolution of recurrent basal cell carcinoma and therapeutic implications for incompletely excised lesions [J].
Boulinguez, S ;
Grison-Tabone, C ;
Lamant, L ;
Valmary, S ;
Viraben, R ;
Bonnetblanc, JM ;
Bédane, C .
BRITISH JOURNAL OF DERMATOLOGY, 2004, 151 (03) :623-626